Samson, T.; Aali, M.; McBride, D.; Arnason, T.; Clarke, S.E.; Ramjeesingh, R.; Gonzalez-Chavez, L.; Azizieh, Y.; Walsh, M.J.; Livingstone, S.M.;
et al. Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. Curr. Oncol. 2026, 33, 88.
https://doi.org/10.3390/curroncol33020088
AMA Style
Samson T, Aali M, McBride D, Arnason T, Clarke SE, Ramjeesingh R, Gonzalez-Chavez L, Azizieh Y, Walsh MJ, Livingstone SM,
et al. Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. Current Oncology. 2026; 33(2):88.
https://doi.org/10.3390/curroncol33020088
Chicago/Turabian Style
Samson, Thomas, Maral Aali, Darien McBride, Thomas Arnason, Sharon E. Clarke, Ravi Ramjeesingh, Lisette Gonzalez-Chavez, Yara Azizieh, Mark J. Walsh, Scott M. Livingstone,
and et al. 2026. "Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma" Current Oncology 33, no. 2: 88.
https://doi.org/10.3390/curroncol33020088
APA Style
Samson, T., Aali, M., McBride, D., Arnason, T., Clarke, S. E., Ramjeesingh, R., Gonzalez-Chavez, L., Azizieh, Y., Walsh, M. J., Livingstone, S. M., Hiebert, S. E., Boudreau, J. E., & Gala-Lopez, B. L.
(2026). Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. Current Oncology, 33(2), 88.
https://doi.org/10.3390/curroncol33020088
